Mobile website
Archive > Volume 31 Issue 3 > 2024,31(3):211-218. DOI:10.3872/j.issn.1007-385X.2024.03.001 Prev Next
Expert Forum
Major progress made in γδT cell-based tumor immunotherapy in 2023
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
γδT cell is a unique kind of innate immune T cell expressing T cell receptor γ and δ chain heterodimer. There is a lack of comprehensive and systematic basic research in the development, differentiation, proliferation, activation, effect and exhaustion of γδT cell that many main questions are remaining unclear. However, mature γδT cells predominantly colonize mucosal tissues with a high incidence of tumors, such as skin, digestive tract, respiratory tract, and reproductive tract, and can directly recognize and kill a variety of tumor cells without major histocompatibility complex (MHC) restriction, which has irreplaceable advantages in the field of tumor immunotherapy. In recent years, the application of γδT cells have surged and developed rapidly, which, in turn, contributed to the deepening of basic research, and thus some brilliant progress has been made. In this paper, we enumerate the major progress of γδT cells in tumor immunotherapy in 2023, mainly focusing on the mechanism of tumor antigen recognition by γδT cells, the functional regulation of γδT cells in the tumor microenvironment, the mechanism of anti-tumor cytotoxicity of γδT cells, and the new synergistic strategy of tumor immunotherapy based on γδT cells. It is expected to promote the further development of γδT cells in the field of tumour immunotherapy and provide new insights into the synergistic strategy of γδT cells in clinical application.
Keywords:
Project Supported:
Clc Number:
